Association between circulating immune cells and the risk of prostate cancer: a Mendelian randomization study
There is still limited research on the association between immune cells and the risk of prostate cancer. Further investigations are warranted to comprehend the intricate associations at play. We used a bidirectional two-sample Mendelian randomization (MR) analysis to investigate the causal relations...
Uložené v:
| Vydané v: | Frontiers in endocrinology (Lausanne) Ročník 15; s. 1358416 |
|---|---|
| Hlavní autori: | , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Switzerland
Frontiers Media S.A
2024
|
| Predmet: | |
| ISSN: | 1664-2392, 1664-2392 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | There is still limited research on the association between immune cells and the risk of prostate cancer. Further investigations are warranted to comprehend the intricate associations at play.
We used a bidirectional two-sample Mendelian randomization (MR) analysis to investigate the causal relationship between immune cell phenotypes and prostate cancer. The summary data for immune cell phenotypes was derived from a study cohort, including 3,757 individuals from Sardinia with data on 731 immune cell phenotypes. The summary data for prostate cancer were obtained from the UK Biobank database. Sensitivity analyses were conducted, and the combination of MR-Egger and MR-Presso was used to assess horizontal pleiotropy. Cochran's Q test was employed to evaluate heterogeneity, and the results were subjected to FDR correction.
Our study identified two immune cell phenotypes significantly associated with the risk of prostate cancer, namely CD25 on naive-mature B cells (OR = 0.998, 95% CI, 0.997-0.999,
= 2.33E-05, FDR = 0.017) and HLA DR on CD14- CD16- cells (OR = 1.001, 95% CI, 1.000-1.002,
= 8.01E-05, FDR = 0.03). When adjusting FDR to 0.2, we additionally found six immune cell phenotypes influencing the incidence of prostate cancer. These include FSC-A on B cells (OR = 1.002, 95% CI, 1.001-1.002,
= 7.77E-04, FDR = 0.133), HLA DR on plasmacytoid dendritic cells (OR = 1.001, 95% CI, 1.000-1.001,
= 0.001, FDR = 0.133), CD14+ CD16- monocyte % monocytes (OR = 1.002, 95% CI, 1.001-1.003,
= 0.001, FDR = 0.133), and HVEM on effector memory CD4+ T cells (OR = 1.001, 95% CI, 1.000-1.002,
= 0.002, FDR = 0.169), which are positively correlated with the risk of prostate cancer. Conversely, CD25 on IgD+ B cells (OR = 0.998, 95% CI, 0.997-0.999,
= 0.002, FDR = 0.169) and Monocytic Myeloid-Derived Suppressor Cells AC (OR = 0.999, 95% CI, 0.999-1.000,
= 0.002, FDR = 0.17) are negatively correlated with the risk of prostate cancer.
This study has revealed causal relationships between immune cell phenotypes and prostate cancer, supplying novel insights that might aid in identifying potential therapeutic targets of prostate cancer. |
|---|---|
| AbstractList | There is still limited research on the association between immune cells and the risk of prostate cancer. Further investigations are warranted to comprehend the intricate associations at play.BackgroundThere is still limited research on the association between immune cells and the risk of prostate cancer. Further investigations are warranted to comprehend the intricate associations at play.We used a bidirectional two-sample Mendelian randomization (MR) analysis to investigate the causal relationship between immune cell phenotypes and prostate cancer. The summary data for immune cell phenotypes was derived from a study cohort, including 3,757 individuals from Sardinia with data on 731 immune cell phenotypes. The summary data for prostate cancer were obtained from the UK Biobank database. Sensitivity analyses were conducted, and the combination of MR-Egger and MR-Presso was used to assess horizontal pleiotropy. Cochran's Q test was employed to evaluate heterogeneity, and the results were subjected to FDR correction.MethodsWe used a bidirectional two-sample Mendelian randomization (MR) analysis to investigate the causal relationship between immune cell phenotypes and prostate cancer. The summary data for immune cell phenotypes was derived from a study cohort, including 3,757 individuals from Sardinia with data on 731 immune cell phenotypes. The summary data for prostate cancer were obtained from the UK Biobank database. Sensitivity analyses were conducted, and the combination of MR-Egger and MR-Presso was used to assess horizontal pleiotropy. Cochran's Q test was employed to evaluate heterogeneity, and the results were subjected to FDR correction.Our study identified two immune cell phenotypes significantly associated with the risk of prostate cancer, namely CD25 on naive-mature B cells (OR = 0.998, 95% CI, 0.997-0.999, P = 2.33E-05, FDR = 0.017) and HLA DR on CD14- CD16- cells (OR = 1.001, 95% CI, 1.000-1.002, P = 8.01E-05, FDR = 0.03). When adjusting FDR to 0.2, we additionally found six immune cell phenotypes influencing the incidence of prostate cancer. These include FSC-A on B cells (OR = 1.002, 95% CI, 1.001-1.002, P = 7.77E-04, FDR = 0.133), HLA DR on plasmacytoid dendritic cells (OR = 1.001, 95% CI, 1.000-1.001, P = 0.001, FDR = 0.133), CD14+ CD16- monocyte % monocytes (OR = 1.002, 95% CI, 1.001-1.003, P = 0.001, FDR = 0.133), and HVEM on effector memory CD4+ T cells (OR = 1.001, 95% CI, 1.000-1.002, P = 0.002, FDR = 0.169), which are positively correlated with the risk of prostate cancer. Conversely, CD25 on IgD+ B cells (OR = 0.998, 95% CI, 0.997-0.999, P = 0.002, FDR = 0.169) and Monocytic Myeloid-Derived Suppressor Cells AC (OR = 0.999, 95% CI, 0.999-1.000, P = 0.002, FDR = 0.17) are negatively correlated with the risk of prostate cancer.ResultsOur study identified two immune cell phenotypes significantly associated with the risk of prostate cancer, namely CD25 on naive-mature B cells (OR = 0.998, 95% CI, 0.997-0.999, P = 2.33E-05, FDR = 0.017) and HLA DR on CD14- CD16- cells (OR = 1.001, 95% CI, 1.000-1.002, P = 8.01E-05, FDR = 0.03). When adjusting FDR to 0.2, we additionally found six immune cell phenotypes influencing the incidence of prostate cancer. These include FSC-A on B cells (OR = 1.002, 95% CI, 1.001-1.002, P = 7.77E-04, FDR = 0.133), HLA DR on plasmacytoid dendritic cells (OR = 1.001, 95% CI, 1.000-1.001, P = 0.001, FDR = 0.133), CD14+ CD16- monocyte % monocytes (OR = 1.002, 95% CI, 1.001-1.003, P = 0.001, FDR = 0.133), and HVEM on effector memory CD4+ T cells (OR = 1.001, 95% CI, 1.000-1.002, P = 0.002, FDR = 0.169), which are positively correlated with the risk of prostate cancer. Conversely, CD25 on IgD+ B cells (OR = 0.998, 95% CI, 0.997-0.999, P = 0.002, FDR = 0.169) and Monocytic Myeloid-Derived Suppressor Cells AC (OR = 0.999, 95% CI, 0.999-1.000, P = 0.002, FDR = 0.17) are negatively correlated with the risk of prostate cancer.This study has revealed causal relationships between immune cell phenotypes and prostate cancer, supplying novel insights that might aid in identifying potential therapeutic targets of prostate cancer.ConclusionThis study has revealed causal relationships between immune cell phenotypes and prostate cancer, supplying novel insights that might aid in identifying potential therapeutic targets of prostate cancer. There is still limited research on the association between immune cells and the risk of prostate cancer. Further investigations are warranted to comprehend the intricate associations at play. We used a bidirectional two-sample Mendelian randomization (MR) analysis to investigate the causal relationship between immune cell phenotypes and prostate cancer. The summary data for immune cell phenotypes was derived from a study cohort, including 3,757 individuals from Sardinia with data on 731 immune cell phenotypes. The summary data for prostate cancer were obtained from the UK Biobank database. Sensitivity analyses were conducted, and the combination of MR-Egger and MR-Presso was used to assess horizontal pleiotropy. Cochran's Q test was employed to evaluate heterogeneity, and the results were subjected to FDR correction. Our study identified two immune cell phenotypes significantly associated with the risk of prostate cancer, namely CD25 on naive-mature B cells (OR = 0.998, 95% CI, 0.997-0.999, = 2.33E-05, FDR = 0.017) and HLA DR on CD14- CD16- cells (OR = 1.001, 95% CI, 1.000-1.002, = 8.01E-05, FDR = 0.03). When adjusting FDR to 0.2, we additionally found six immune cell phenotypes influencing the incidence of prostate cancer. These include FSC-A on B cells (OR = 1.002, 95% CI, 1.001-1.002, = 7.77E-04, FDR = 0.133), HLA DR on plasmacytoid dendritic cells (OR = 1.001, 95% CI, 1.000-1.001, = 0.001, FDR = 0.133), CD14+ CD16- monocyte % monocytes (OR = 1.002, 95% CI, 1.001-1.003, = 0.001, FDR = 0.133), and HVEM on effector memory CD4+ T cells (OR = 1.001, 95% CI, 1.000-1.002, = 0.002, FDR = 0.169), which are positively correlated with the risk of prostate cancer. Conversely, CD25 on IgD+ B cells (OR = 0.998, 95% CI, 0.997-0.999, = 0.002, FDR = 0.169) and Monocytic Myeloid-Derived Suppressor Cells AC (OR = 0.999, 95% CI, 0.999-1.000, = 0.002, FDR = 0.17) are negatively correlated with the risk of prostate cancer. This study has revealed causal relationships between immune cell phenotypes and prostate cancer, supplying novel insights that might aid in identifying potential therapeutic targets of prostate cancer. BackgroundThere is still limited research on the association between immune cells and the risk of prostate cancer. Further investigations are warranted to comprehend the intricate associations at play.MethodsWe used a bidirectional two-sample Mendelian randomization (MR) analysis to investigate the causal relationship between immune cell phenotypes and prostate cancer. The summary data for immune cell phenotypes was derived from a study cohort, including 3,757 individuals from Sardinia with data on 731 immune cell phenotypes. The summary data for prostate cancer were obtained from the UK Biobank database. Sensitivity analyses were conducted, and the combination of MR-Egger and MR-Presso was used to assess horizontal pleiotropy. Cochran’s Q test was employed to evaluate heterogeneity, and the results were subjected to FDR correction.ResultsOur study identified two immune cell phenotypes significantly associated with the risk of prostate cancer, namely CD25 on naive-mature B cells (OR = 0.998, 95% CI, 0.997-0.999, P = 2.33E-05, FDR = 0.017) and HLA DR on CD14- CD16- cells (OR = 1.001, 95% CI, 1.000-1.002, P = 8.01E-05, FDR = 0.03). When adjusting FDR to 0.2, we additionally found six immune cell phenotypes influencing the incidence of prostate cancer. These include FSC-A on B cells (OR = 1.002, 95% CI, 1.001-1.002, P = 7.77E-04, FDR = 0.133), HLA DR on plasmacytoid dendritic cells (OR = 1.001, 95% CI, 1.000-1.001, P = 0.001, FDR = 0.133), CD14+ CD16- monocyte % monocytes (OR = 1.002, 95% CI, 1.001-1.003, P = 0.001, FDR = 0.133), and HVEM on effector memory CD4+ T cells (OR = 1.001, 95% CI, 1.000-1.002, P = 0.002, FDR = 0.169), which are positively correlated with the risk of prostate cancer. Conversely, CD25 on IgD+ B cells (OR = 0.998, 95% CI, 0.997-0.999, P = 0.002, FDR = 0.169) and Monocytic Myeloid-Derived Suppressor Cells AC (OR = 0.999, 95% CI, 0.999-1.000, P = 0.002, FDR = 0.17) are negatively correlated with the risk of prostate cancer.ConclusionThis study has revealed causal relationships between immune cell phenotypes and prostate cancer, supplying novel insights that might aid in identifying potential therapeutic targets of prostate cancer. |
| Author | Ren, Congzhe Hao, Xuexue Liu, Xiaoqiang Zhang, Hao Zhou, Hang Li, Muwei |
| Author_xml | – sequence: 1 givenname: Xuexue surname: Hao fullname: Hao, Xuexue – sequence: 2 givenname: Congzhe surname: Ren fullname: Ren, Congzhe – sequence: 3 givenname: Hang surname: Zhou fullname: Zhou, Hang – sequence: 4 givenname: Muwei surname: Li fullname: Li, Muwei – sequence: 5 givenname: Hao surname: Zhang fullname: Zhang, Hao – sequence: 6 givenname: Xiaoqiang surname: Liu fullname: Liu, Xiaoqiang |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38405157$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9UUtvFiEUJabG1to_4MKwdPN98pwZ3DWNjyY1bnRN7sCdSp2BCkxM_fXyPWyMC9nAvZxzLpzznJzEFJGQl5xtpRzMmwmjT1vBhNpyqQfFuyfkjHed2ghpxMlf51NyUcoda0sxbszwjJzKQTHNdX9GlstSkgtQQ4p0xPoTMVIXslvn1ou3NCzLGpE6nOdCIXpavyHNoXynaaL3OZUKtV1DdJjfUqCf2rtwDhBpbui0hF8H7VJX__CCPJ1gLnhx3M_J1_fvvlx93Nx8_nB9dXmzcYrLukHNpYfOGNZ3bAQGIH0v1ATOq15pDlqormul4qOanJY975zjg-97Nynh5Dm5Puj6BHf2PocF8oNNEOy-kfKthVyDm9HioEctJ8_HNkF4D2YYRtcbwSfsmtFN6_VBq332x4ql2iWUnR0QMa3FCiN3KRjRN-irI3QdF_SPg__Y3QDiAHDNuJJxeoRwZnex2n2sdidoj7E20vAPyYW6N7VmCPP_qL8BXZWpTg |
| CitedBy_id | crossref_primary_10_1016_j_cyto_2025_156942 crossref_primary_10_1186_s41927_025_00521_y crossref_primary_10_3389_fmicb_2024_1445304 crossref_primary_10_1007_s12672_025_03175_x crossref_primary_10_1038_s41598_025_01329_z crossref_primary_10_2147_CCID_S532061 crossref_primary_10_3389_fendo_2024_1438097 crossref_primary_10_1186_s12876_025_03776_4 crossref_primary_10_3389_fcimb_2024_1452480 crossref_primary_10_1097_MD_0000000000040064 crossref_primary_10_1097_MD_0000000000044282 crossref_primary_10_1097_MD_0000000000043634 crossref_primary_10_3389_fonc_2024_1435313 crossref_primary_10_1016_j_archger_2025_105788 crossref_primary_10_1007_s12672_025_03046_5 crossref_primary_10_1038_s41598_025_97759_w crossref_primary_10_1016_j_heliyon_2024_e39732 crossref_primary_10_1097_MD_0000000000042618 |
| Cites_doi | 10.3389/fimmu.2023.1205266 10.3389/fimmu.2022.1017132 10.1002/pros.21078 10.1158/0008-5472.CAN-20-0730 10.1681/ASN.2016010098 10.1007/s00262-014-1591-2 10.1186/s12888-023-05081-4 10.1136/bmjebm-2022-112149 10.1016/j.eururo.2023.04.021 10.1016/j.isci.2020.101296 10.1016/j.celrep.2022.110854 10.1530/ERC-21-0149 10.1155/2022/2269237 10.3389/fgene.2022.803238 10.1136/jitc-2019-000472 10.3390/ijms19051468 10.1101/cshperspect.a030361 10.1002/cncr.34345 10.1002/jrsm.1346 10.1002/ptr.7618 10.1016/j.clim.2021.108677 10.1016/j.aller.2018.04.003 10.1016/j.csbj.2022.05.015 10.1101/gad.314617.118 10.1038/d41573-020-00206-w 10.3390/cancers15030920 10.1002/path.5757 10.3390/cancers14071681 10.3389/fcell.2022.991330 10.1038/s41598-021-87219-6 10.1038/s41467-022-34871-9 10.1038/s41572-021-00249-2 10.1016/j.eururo.2022.02.007 10.1038/s41392-020-00449-4 10.1038/s41588-020-0684-4 10.1002/ijc.34281 10.1038/s41590-023-01472-7 10.1038/s41568-021-00347-z 10.1002/cjp2.160 10.1016/j.canep.2019.101577 10.7554/eLife.86416 |
| ContentType | Journal Article |
| Copyright | Copyright © 2024 Hao, Ren, Zhou, Li, Zhang and Liu. |
| Copyright_xml | – notice: Copyright © 2024 Hao, Ren, Zhou, Li, Zhang and Liu. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 DOA |
| DOI | 10.3389/fendo.2024.1358416 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Open Access: DOAJ - Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1664-2392 |
| ExternalDocumentID | oai_doaj_org_article_e85b53fd1b7242dda988bc7921fe6389 38405157 10_3389_fendo_2024_1358416 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ADBBV ADRAZ AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E OK1 PGMZT RPM ACXDI CGR CUY CVF ECM EIF IPNFZ NPM RIG 7X8 |
| ID | FETCH-LOGICAL-c413t-e513da6990760ba0aa3d724facd47451a52466fac41b4fc53716cc18d77cf42c3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 20 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001169423400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1664-2392 |
| IngestDate | Fri Oct 03 12:53:50 EDT 2025 Fri Sep 05 11:20:52 EDT 2025 Thu Apr 03 07:10:19 EDT 2025 Tue Nov 18 21:29:25 EST 2025 Sat Nov 29 03:00:12 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | immune cells prostate cancer reverse causality Mendelian randomization study causality |
| Language | English |
| License | Copyright © 2024 Hao, Ren, Zhou, Li, Zhang and Liu. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c413t-e513da6990760ba0aa3d724facd47451a52466fac41b4fc53716cc18d77cf42c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://doaj.org/article/e85b53fd1b7242dda988bc7921fe6389 |
| PMID | 38405157 |
| PQID | 2932024927 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_e85b53fd1b7242dda988bc7921fe6389 proquest_miscellaneous_2932024927 pubmed_primary_38405157 crossref_primary_10_3389_fendo_2024_1358416 crossref_citationtrail_10_3389_fendo_2024_1358416 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-00-00 |
| PublicationDateYYYYMMDD | 2024-01-01 |
| PublicationDate_xml | – year: 2024 text: 2024-00-00 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Frontiers in endocrinology (Lausanne) |
| PublicationTitleAlternate | Front Endocrinol (Lausanne) |
| PublicationYear | 2024 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Molina (B14) 2023; 14 Rebello (B1) 2021; 7 Adimora (B36) 2022; 128 Lor (B20) 2019; 62 Orrù (B21) 2020; 52 Weith (B19) 2023; 12 Li (B40) 2022; 13 Andersen (B13) 2021; 255 Santiago (B34) 2023; 37 Peng (B25) 2023; 152 Sakakura (B31) 2021; 225 Saudi (B12) 2023; 15 Tussiwand (B37) 2023; 24 Özkan (B38) 2018; 19 Prat (B32) 2020; 8 Vickers (B4) 2022; 81 Wang (B22) 2021; 11 Rampoldi (B30) 2022; 39 Wang (B35) 2023; 23 Vuk-Pavlović (B33) 2010; 70 Peña-Romero (B9) 2022; 14 Palomero (B11) 2020; 23 Gonzalez (B6) 2018; 32 Mbutiwi (B23) 2022; 13 Song (B10) 2020; 80 Zhang (B28) 2022; 2022 Idorn (B41) 2014; 63 Kwon (B15) 2021; 28 Kim (B18) 2023; 28 Villanueva (B26) 2021; 20 Bowden (B17) 2019; 10 Bergengren (B5) 2023; 84 Fuss (B29) 2019; 47 Pernar (B3) 2018; 8 Sekula (B16) 2016; 27 Wen (B39) 2020; 6 Hiam-Galvez (B7) 2021; 21 Lee (B27) 2022; 13 Boehm (B24) 2022; 20 Belkahla (B2) 2022; 10 Tang (B8) 2021; 6 |
| References_xml | – volume: 14 year: 2023 ident: B14 article-title: High infiltration of CD209(+) dendritic cells and CD163(+) macrophages in the peritumor area of prostate cancer is predictive of late adverse outcomes publication-title: Front Immunol doi: 10.3389/fimmu.2023.1205266 – volume: 13 year: 2022 ident: B27 article-title: Cysteine-specific (89)Zr-labeled anti-CD25 IgG allows immuno-PET imaging of interleukin-2 receptor-α on T cell lymphomas publication-title: Front Immunol doi: 10.3389/fimmu.2022.1017132 – volume: 70 year: 2010 ident: B33 article-title: Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer publication-title: Prostate doi: 10.1002/pros.21078 – volume: 80 year: 2020 ident: B10 article-title: Systemic immune response and cancer risk: filling the missing piece of immuno-oncology publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-20-0730 – volume: 27 year: 2016 ident: B16 article-title: Mendelian randomization as an approach to assess causality using observational data publication-title: J Am Soc Nephrol: JASN doi: 10.1681/ASN.2016010098 – volume: 63 year: 2014 ident: B41 article-title: Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer publication-title: Cancer Immunol Immunother CII doi: 10.1007/s00262-014-1591-2 – volume: 23 start-page: 590 year: 2023 ident: B35 article-title: Causal role of immune cells in schizophrenia: Mendelian randomization (MR) study publication-title: BMC Psychiatry doi: 10.1186/s12888-023-05081-4 – volume: 28 year: 2023 ident: B18 article-title: How to interpret studies using Mendelian randomisation publication-title: BMJ Evidence-Based Med doi: 10.1136/bmjebm-2022-112149 – volume: 84 start-page: 191 year: 2023 ident: B5 article-title: 2022 Update on prostate cancer epidemiology and risk factors-A systematic review publication-title: Eur Urol doi: 10.1016/j.eururo.2023.04.021 – volume: 23 start-page: 101296 year: 2020 ident: B11 article-title: Immune cell associations with cancer risk publication-title: iScience doi: 10.1016/j.isci.2020.101296 – volume: 39 start-page: 110854 year: 2022 ident: B30 article-title: γδ T cells license immature B cells to produce a broad range of polyreactive antibodies publication-title: Cell Rep doi: 10.1016/j.celrep.2022.110854 – volume: 28 start-page: T95 year: 2021 ident: B15 article-title: The tumor microenvironment and immune responses in prostate cancer patients publication-title: Endocrine-related Cancer doi: 10.1530/ERC-21-0149 – volume: 2022 start-page: 2269237 year: 2022 ident: B28 article-title: Differences of circulating CD25(hi) bregs and their correlations with CD4 effector and regulatory T cells in autoantibody-positive T1D compared with age-matched healthy individuals publication-title: J Immunol Res doi: 10.1155/2022/2269237 – volume: 13 year: 2022 ident: B23 article-title: Mendelian randomization: A review of methods for the prevention, assessment, and discussion of pleiotropy in studies using the fat mass and obesity-associated gene as an instrument for adiposity publication-title: Front Genet doi: 10.3389/fgene.2022.803238 – volume: 8 year: 2020 ident: B32 article-title: Circulating CD14(high) CD16(low) intermediate blood monocytes as a biomarker of ascites immune status and ovarian cancer progression publication-title: J Immunother Cancer doi: 10.1136/jitc-2019-000472 – volume: 19 start-page: 1468 year: 2018 ident: B38 article-title: Immunomodulatory function of myeloid-derived suppressor cells during B cell-mediated immune responses publication-title: Int J Mol Sci doi: 10.3390/ijms19051468 – volume: 8 start-page: a030361 year: 2018 ident: B3 article-title: The epidemiology of prostate cancer publication-title: Cold Spring Harbor Perspect Med doi: 10.1101/cshperspect.a030361 – volume: 128 year: 2022 ident: B36 article-title: Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics publication-title: Cancer doi: 10.1002/cncr.34345 – volume: 10 year: 2019 ident: B17 article-title: Meta-analysis and Mendelian randomization: A review publication-title: Res Synthesis Methods doi: 10.1002/jrsm.1346 – volume: 37 start-page: 399 year: 2023 ident: B34 article-title: Brazilian red propolis exerts a cytotoxic action against prostate cancer cells and upregulates human monocyte functions publication-title: Phytother Res PTR doi: 10.1002/ptr.7618 – volume: 225 start-page: 108677 year: 2021 ident: B31 article-title: Immunological features of circulating monocyte subsets in patients with squamous cell carcinoma of the head and neck publication-title: Clin Immunol (Orlando Fla.) doi: 10.1016/j.clim.2021.108677 – volume: 47 year: 2019 ident: B29 article-title: Association between environmental exposure and CD4+CD25+ regulatory T cells publication-title: Allergologia immunopathologia doi: 10.1016/j.aller.2018.04.003 – volume: 20 year: 2022 ident: B24 article-title: Statistical methods for Mendelian randomization in genome-wide association studies: A review publication-title: Comput Struct Biotechnol J doi: 10.1016/j.csbj.2022.05.015 – volume: 32 year: 2018 ident: B6 article-title: Roles of the immune system in cancer: from tumor initiation to metastatic progression publication-title: Genes Dev doi: 10.1101/gad.314617.118 – volume: 20 start-page: 18 year: 2021 ident: B26 article-title: Anti-CD25 antibody tips the T cell balance publication-title: Nat Rev Drug Discovery doi: 10.1038/d41573-020-00206-w – volume: 15 start-page: 920 year: 2023 ident: B12 article-title: Immune-activated B cells are dominant in prostate cancer publication-title: Cancers doi: 10.3390/cancers15030920 – volume: 255 year: 2021 ident: B13 article-title: Immune cell analyses of the tumor microenvironment in prostate cancer highlight infiltrating regulatory T cells and macrophages as adverse prognostic factors publication-title: J Pathol doi: 10.1002/path.5757 – volume: 14 start-page: 1681 year: 2022 ident: B9 article-title: Dual effect of immune cells within tumour microenvironment: pro- and anti-tumour effects and their triggers publication-title: Cancers doi: 10.3390/cancers14071681 – volume: 10 year: 2022 ident: B2 article-title: Advances and development of prostate cancer, treatment, and strategies: A systemic review publication-title: Front Cell Dev Biol doi: 10.3389/fcell.2022.991330 – volume: 11 start-page: 7585 year: 2021 ident: B22 article-title: Effect of selection bias on two sample summary data based Mendelian randomization publication-title: Sci Rep doi: 10.1038/s41598-021-87219-6 – volume: 13 start-page: 7281 year: 2022 ident: B40 article-title: ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression publication-title: Nat Commun doi: 10.1038/s41467-022-34871-9 – volume: 7 start-page: 8 year: 2021 ident: B1 article-title: Prostate cancer publication-title: Nat Rev Dis Primers doi: 10.1038/s41572-021-00249-2 – volume: 81 year: 2022 ident: B4 article-title: Race, biology, disparities, and prostate cancer publication-title: Eur Urol doi: 10.1016/j.eururo.2022.02.007 – volume: 6 start-page: 72 year: 2021 ident: B8 article-title: Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy publication-title: Signal Transduction Targeted Ther doi: 10.1038/s41392-020-00449-4 – volume: 52 year: 2020 ident: B21 article-title: Complex genetic signatures in immune cells underlie autoimmunity and inform therapy publication-title: Nat Genet doi: 10.1038/s41588-020-0684-4 – volume: 152 year: 2023 ident: B25 article-title: CD25: A potential tumor therapeutic target publication-title: Int J Cancer doi: 10.1002/ijc.34281 – volume: 24 year: 2023 ident: B37 article-title: Plasmacytoid dendritic cells turn red publication-title: Nat Immunol doi: 10.1038/s41590-023-01472-7 – volume: 21 year: 2021 ident: B7 article-title: Systemic immunity in cancer publication-title: Nat Rev Cancer doi: 10.1038/s41568-021-00347-z – volume: 6 year: 2020 ident: B39 article-title: Polymorphonuclear MDSCs are enriched in the stroma and expanded in metastases of prostate cancer publication-title: J Pathol Clin Res doi: 10.1002/cjp2.160 – volume: 62 start-page: 101577 year: 2019 ident: B20 article-title: Reporting and guidelines for mendelian randomization analysis: A systematic review of oncological studies publication-title: Cancer Epidemiol doi: 10.1016/j.canep.2019.101577 – volume: 12 year: 2023 ident: B19 article-title: The next step in Mendelian randomization publication-title: eLife doi: 10.7554/eLife.86416 |
| SSID | ssj0000401998 |
| Score | 2.4423225 |
| Snippet | There is still limited research on the association between immune cells and the risk of prostate cancer. Further investigations are warranted to comprehend the... BackgroundThere is still limited research on the association between immune cells and the risk of prostate cancer. Further investigations are warranted to... |
| SourceID | doaj proquest pubmed crossref |
| SourceType | Open Website Aggregation Database Index Database Enrichment Source |
| StartPage | 1358416 |
| SubjectTerms | B-Lymphocytes causality Databases, Factual HLA-DR Antigens Humans immune cells Male Mendelian Randomization Analysis Mendelian randomization study prostate cancer Prostatic Neoplasms - genetics reverse causality |
| Title | Association between circulating immune cells and the risk of prostate cancer: a Mendelian randomization study |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38405157 https://www.proquest.com/docview/2932024927 https://doaj.org/article/e85b53fd1b7242dda988bc7921fe6389 |
| Volume | 15 |
| WOSCitedRecordID | wos001169423400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1664-2392 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000401998 issn: 1664-2392 databaseCode: DOA dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1664-2392 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000401998 issn: 1664-2392 databaseCode: M~E dateStart: 20100101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEB6aUEIuJX1mm3ZRoLdi1rJkS-otKQm97NJDA3sTsh5hofGG3U2P_e2dkb3L9tDmkovBtozEN7K-mZFmBuBTWQfVRnK9KSEKGbgvjNSpqKIrXWli5YPOxSbUbKbnc_N9r9QXnQnr0wP3wE2irttapMBbhWwSgjNat16ZiqdIbEurL2o9e8ZUXoPRbEBDoo-SQSvMTFLsAgX7VZJKPdBm219MlBP2_1vLzGxzfQIvBjWRXfTDewnPYvcKjqbDRvhruNuDlQ1nrZhfrHyuxtXdsgXFfURGfvk1c11gqOgxOkfOlondU6gHKpnMk8xXX5hjU3KFk8uDIXmF5d0Qnsly-tk3cHN99ePrt2KonFB4JKVNEWsugmuQaVRTtoi6EwHhS84HqWTNXV3JpsFbyVuZfC3QavKe66CUT7Ly4i0cdssungJTytTCc96kEt-0jdGxlVQcwiCxJ8FHwLcoWj-kFafqFj8tmheEvM3IW0LeDsiP4PPum_s-qcZ_W1-ScHYtKSF2foDTxA7TxD42TUZwvhWtxR-I0HddXD6sLeo7Vc6bqEbwrpf5riuB5i8qfOr9UwzhDI6po95_8wEON6uH-BGe-1-bxXo1hgM11-M8i_E6_X31ByKt9lM |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Association+between+circulating+immune+cells+and+the+risk+of+prostate+cancer%3A+a+Mendelian+randomization+study&rft.jtitle=Frontiers+in+endocrinology+%28Lausanne%29&rft.au=Hao%2C+Xuexue&rft.au=Ren%2C+Congzhe&rft.au=Zhou%2C+Hang&rft.au=Li%2C+Muwei&rft.date=2024&rft.issn=1664-2392&rft.eissn=1664-2392&rft.volume=15&rft.spage=1358416&rft_id=info:doi/10.3389%2Ffendo.2024.1358416&rft_id=info%3Apmid%2F38405157&rft.externalDocID=38405157 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-2392&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-2392&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-2392&client=summon |